By Kelly Cloonan
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
The stock rose 7% to $2.99 on Friday. Shares have lost 1% over the past 12 months.
The biopharmaceutical company said Thursday that the European Patent Office has confirmed the validity of its amended patent for split poly-A tail technology, which improves expression of the protein encoded on an mRNA construct to enhance the efficacy of certain vaccines.
BioNTech first filed a lawsuit regarding the patent in 2023.
After Thursday's ruling, the Regional Court Düsseldorf will decide if the amended patent has been infringed in a hearing scheduled for July 1.
"Today's decision marks an important step on our path that we expect will lead to recognition of CureVac's major contribution to safe and efficacious Covid-19 vaccines as the earliest pioneer in mRNA technology," said CureVac Chief Executive Dr. Alexander Zehnder.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 28, 2025 12:45 ET (16:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。